Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 07 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.88 Insider Own50.26% Shs Outstand83.62M Perf Week6.04%
Market Cap293.51M Forward P/E- EPS next Y-0.57 Insider Trans0.00% Shs Float41.59M Perf Month29.04%
Income-74.24M PEG- EPS next Q0.02 Inst Own19.95% Short Float / Ratio1.36% / 11.48 Perf Quarter6.69%
Sales0.00M P/S- EPS this Y29.55% Inst Trans1.20% Short Interest0.56M Perf Half Y58.11%
Book/sh1.75 P/B2.00 EPS next Y13.34% ROA-40.66% Target Price10.82 Perf Year52.61%
Cash/sh1.04 P/C3.36 EPS next 5Y- ROE-44.93% 52W Range1.68 - 3.83 Perf YTD72.06%
Dividend- P/FCF- EPS past 5Y-13.66% ROI-53.27% 52W High-8.35% Beta0.67
Dividend %- Quick Ratio7.36 Sales past 5Y232.51% Gross Margin- 52W Low108.93% ATR0.22
Employees156 Current Ratio7.36 Sales Q/Q-100.00% Oper. Margin-7376960.89% RSI (14)65.96 Volatility6.98% 6.58%
OptionableYes Debt/Eq0.02 EPS Q/Q-20.99% Profit Margin-7157319.53% Rel Volume1.72 Prev Close3.57
ShortableYes LT Debt/Eq0.01 EarningsNov 03 BMO Payout- Avg Volume49.23K Price3.51
Recom1.00 SMA2012.19% SMA5020.81% SMA20032.99% Volume84,866 Change-1.68%
Date Action Analyst Rating Change Price Target Change
Feb-01-19Downgrade UBS Buy → Neutral
Jan-04-19Initiated UBS Buy
Apr-05-18Initiated H.C. Wainwright Buy $18
Mar-23-18Downgrade Credit Suisse Outperform → Neutral
Oct-18-16Initiated Leerink Partners Outperform
Oct-18-16Initiated Jefferies Buy $25
Oct-18-16Initiated Credit Suisse Outperform $18
Dec-05-23 05:59AM
Dec-01-23 07:00AM
Nov-28-23 07:33PM
Nov-20-23 06:00AM
Nov-07-23 07:00AM
08:37AM Loading…
Nov-03-23 08:37AM
Nov-02-23 07:00AM
Oct-27-23 07:00AM
Oct-24-23 09:40AM
Oct-23-23 10:00AM
Oct-20-23 10:00AM
Oct-18-23 08:26AM
Oct-17-23 07:00AM
Oct-05-23 07:00AM
01:09PM Loading…
Sep-05-23 01:09PM
Aug-04-23 08:15AM
Jul-28-23 07:00AM
Jul-26-23 07:00AM
Jul-03-23 07:00AM
Jun-30-23 03:13PM
Jun-27-23 07:00AM
Jun-23-23 04:30PM
Jun-16-23 10:45AM
May-04-23 09:02AM
Apr-28-23 07:14AM
07:00AM Loading…
Apr-26-23 08:01PM
Apr-07-23 08:29AM
Apr-05-23 07:00AM
Mar-20-23 08:00AM
Mar-16-23 07:00AM
Mar-08-23 07:00AM
Feb-07-23 07:00AM
Feb-02-23 08:15AM
Jan-27-23 09:57AM
Jan-26-23 07:00AM
Jan-18-23 07:00AM
Jan-07-23 08:45AM
Nov-30-22 07:00AM
Nov-25-22 07:17AM
Nov-23-22 07:30AM
Nov-08-22 07:58AM
Oct-29-22 08:06AM
Oct-28-22 09:25AM
Oct-04-22 08:36AM
Sep-26-22 07:30AM
Sep-01-22 08:00AM
Aug-24-22 04:05PM
Aug-11-22 07:30AM
Aug-02-22 11:00AM
Jul-31-22 08:12AM
Jul-28-22 08:45AM
Jul-22-22 07:30AM
Jun-24-22 04:30PM
Jun-21-22 10:35AM
Jun-17-22 08:31AM
Jun-16-22 08:20AM
Jun-01-22 08:26AM
May-31-22 07:30AM
May-17-22 09:00AM
May-09-22 11:00AM
Apr-28-22 07:30AM
Apr-27-22 07:55AM
Apr-08-22 07:30AM
Mar-30-22 07:58AM
Mar-22-22 07:30AM
Mar-21-22 07:30AM
Mar-16-22 07:41AM
Feb-28-22 07:30AM
Feb-21-22 04:30AM
Feb-15-22 02:54PM
Feb-04-22 07:30AM
Feb-02-22 08:58AM
Dec-15-21 07:49AM
Nov-15-21 06:01AM
Nov-12-21 08:21AM
Nov-10-21 11:20AM
Nov-08-21 08:25AM
Nov-07-21 07:53AM
Nov-05-21 03:00PM
Nov-04-21 06:00AM
Nov-02-21 07:30AM
Oct-29-21 06:00AM
Oct-25-21 07:00AM
Oct-24-21 08:04AM
Sep-03-21 07:52AM
Sep-02-21 07:00AM
Sep-01-21 11:30AM
AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.